Marek Trněný

Research interests

Publications

• Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

  New England Journal of Medicine · 2022 · https://doi.org/10.1056/nejmoa2206913

• Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial

  The Lancet Oncology · 2022 · https://doi.org/10.1016/s1470-2045(22)00293-5

• A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study

  Blood · 2020 · https://doi.org/10.1182/blood.2020006844

• AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma

  Journal of Clinical Oncology · 2019 · https://doi.org/10.1200/jco.19.00010

• Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial

  The Lancet Oncology · 2018 · https://doi.org/10.1016/s1470-2045(18)30618-1

• Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial

  Journal of Clinical Oncology · 2018 · https://doi.org/10.1200/jco.2017.76.0793

• Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma

  Journal of Clinical Oncology · 2017 · https://doi.org/10.1200/jco.2017.73.3402

• Obinutuzumab for the First-Line Treatment of Follicular Lymphoma

  New England Journal of Medicine · 2017 · https://doi.org/10.1056/nejmoa1614598

• Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project

  Cytometry Part B Clinical Cytometry · 2017 · https://doi.org/10.1002/cyto.b.21595

• Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial

  The Lancet Oncology · 2016 · https://doi.org/10.1016/s1470-2045(16)30167-x

• First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial

  The Lancet Oncology · 2016 · https://doi.org/10.1016/s1470-2045(16)30051-1

• Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study

  The Lancet · 2015 · https://doi.org/10.1016/s0140-6736(15)00667-4

• Confirmation of the Mantle-Cell Lymphoma International Prognostic Index in Randomized Trials of the European Mantle-Cell Lymphoma Network

  Journal of Clinical Oncology · 2014 · https://doi.org/10.1200/jco.2013.52.2466

• Treatment of Older Patients with Mantle-Cell Lymphoma

  New England Journal of Medicine · 2012 · https://doi.org/10.1056/nejmoa1200920

• CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group

  The Lancet Oncology · 2011 · https://doi.org/10.1016/s1470-2045(11)70235-2

• Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era

  Journal of Clinical Oncology · 2010 · https://doi.org/10.1200/jco.2010.28.1618

• Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia

  Journal of Clinical Oncology · 2010 · https://doi.org/10.1200/jco.2009.25.3187

• Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

  The Lancet · 2010 · https://doi.org/10.1016/s0140-6736(10)61381-5

• Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study

  Blood · 2009 · https://doi.org/10.1182/blood-2009-06-230250

• CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

  The Lancet Oncology · 2006 · https://doi.org/10.1016/s1470-2045(06)70664-7

Current projects

No projects listed.